Advanced cell therapy; marketing MACI (cartilage repair) and Epicel (skin replacement) in TAMs of $2b+. Record Q4 & 2019 MACI and Epicel revs of $39.4m and $117.9m. 2020 revenue guidance for MACI® and Epicel® raised to $141 to $146m. Expanding MACI salesforce to 76 from 49 reps. NexoBrid BLA filing targeted for mid-2020.
US - New England
Biotechnology, Medical Device, Medical Technology
500MM - 1B
64 Sidney Street
Cambridge, MA 02139
Top 10 Holders of Vericel Corporation
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by